Richard E Gilbert

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1893287/publications.pdf

Version: 2024-02-01

44 papers	3,583 citations	218381 26 h-index	253896 43 g-index
44 all docs	44 docs citations	44 times ranked	5697 citing authors

#	Article	IF	Citations
1	Overexpression of the Severe Acute Respiratory Syndrome Coronavirus-2 Receptor, Angiotensin-Converting Enzyme 2, in Diabetic Kidney Disease: Implications for Kidney Injury in Novel Coronavirus Disease 2019. Canadian Journal of Diabetes, 2021, 45, 162-166.e1.	0.4	19
2	The Goto Kakizaki rat: Impact of age upon changes in cardiac and renal structure, function. PLoS ONE, 2021, 16, e0252711.	1.1	5
3	Empagliflozin Reduces Myocardial Extracellular Volume in Patients WithÂType 2 Diabetes and CoronaryÂArtery Disease. JACC: Cardiovascular Imaging, 2021, 14, 1164-1173.	2.3	51
4	Renal histology in diabetic nephropathy predicts progression to end-stage kidney disease but not the rate of renal function decline. BMC Nephrology, 2020, 21, 285.	0.8	13
5	Hypertension Canadaâ€™s 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 2020, 36, 596-624.	0.8	324
6	The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial. Nephrology Dialysis Transplantation, 2020, 35, 895-897.	0.4	22
7	Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction. Cardiovascular Diabetology, 2020, 19, 13.	2.7	42
8	Diabetic kidney disease 2.0: the treatment paradigm shifts. Lancet Diabetes and Endocrinology,the, 2019, 7, 820-821.	5.5	3
9	Impaired <scp>SIRT</scp> 1 activity leads to diminution in glomerular endowment without accelerating ageâ€associated <scp>GFR</scp> decline. Physiological Reports, 2019, 7, e14044.	0.7	4
10	Acute kidney injury with sodiumâ€glucose coâ€transporterâ€2 inhibitors: A metaâ€analysis of cardiovascular outcome trials. Diabetes, Obesity and Metabolism, 2019, 21, 1996-2000.	2.2	55
11	Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent ModelÂof Heart Failure With PreservedÂEjectionÂFraction. JACC Basic To Translational Science, 2019, 4, 27-37.	1.9	79
12	Reduction in the incidence of myocardial infarction with sodiumâ€“glucose linked cotransporter-2 inhibitors: evident and plausible. Cardiovascular Diabetology, 2019, 18, 6.	2.7	9
13	Hypertension Canadaâ€™s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 2018, 34, 506-525.	0.8	474
14	Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization. Circulation, 2018, 137, 88-90.	1.6	30
15	Reversing CXCL10 Deficiency Ameliorates Kidney Disease in Diabetic Mice. American Journal of Pathology, 2018, 188, 2763-2773.	1.9	14
16	SIRT1 activation attenuates Î± cell hyperplasia, hyperglucagonaemia and hyperglycaemia in STZ-diabetic mice. Scientific Reports, 2018, 8, 13972.	1.6	13
17	Dual inhibition of sodiumâ€“glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction. Cardiovascular Diabetology, 2018, 17, 99.	2.7	32
18	Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials. Diabetes Therapy, 2017, 8, 451-458.	1.2	27

#	Article	IF	Citations
19	Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. Canadian Journal of Cardiology, 2017, 33, 557-576.	0.8	269
20	Sirtuin 1 Activation Reduces Transforming Growth Factor-Î²1â€“Induced Fibrogenesis and Affords Organ Protection in a Model of Progressive, Experimental Kidney and Associated Cardiac Disease. American Journal of Pathology, 2017, 187, 80-90.	1.9	42
21	Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study. American Journal of Medicine, 2017, 130, 1465.e27-1465.e39.	0.6	17
22	Henry Krum, Pioneering Heart Failure Researcher. European Journal of Heart Failure, 2016, 18, 125-126.	2.9	0
23	SGLT2 inhibitors: Î² blockers for the kidney?. Lancet Diabetes and Endocrinology,the, 2016, 4, 814.	5.5	30
24	Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies. Canadian Journal of Diabetes, 2016, 40, 247-257.	0.4	18
25	Recombinant Nâ€“Terminal Slit2 Inhibits TGF-Î²â€“Induced Fibroblast Activation and Renal Fibrosis. Journal of the American Society of Nephrology: JASN, 2016, 27, 2609-2615.	3.0	27
26	Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2016, 32, 569-588.	0.8	400
27	Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease. PLoS ONE, 2016, 11, e0144640.	1.1	47
28	Conditioned Medium from Early-Outgrowth Bone Marrow Cells Is Retinal Protective in Experimental Model of Diabetes. PLoS ONE, 2016, 11, e0147978.	1.1	13
29	Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet, The, 2015, 385, 2107-2117.	6.3	240
30	Heart failure in <scp>SAVORâ€TIMI</scp> 53: The hindsight of diabetic retinopathySAVORâ€TIMI 53ç"ç©¶ä¸ç¤¾ä¿ƒè¿°ç«ï¼šç³–å°¿ç– of Diabetes, 2015, 7, 304-306.	0.8	1
31	The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2015, 31, 549-568.	0.8	431
32	Sodiumâ€"glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?. Kidney International, 2014, 86, 693-700.	2.6	93
33	Heparan sulfate side chains have a critical role in the inhibitory effects of perlecan on vascular smooth muscle cell response to arterial injury. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 307, H337-H345.	1.5	11
34	The perils of clinical trials. Kidney International, 2014, 85, 745-747.	2.6	5
35	The 2014 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and TreatmentÂof Hypertension. Canadian Journal of Cardiology, 2014, 30, 485-501.	0.8	221
36	Augmenting Endothelial Repair in Diabetes: Role of Bone Marrow-Derived Cells. Canadian Journal of Diabetes, 2013, 37, 315-318.	0.4	8

#	Article	IF	Citations
37	DPPâ€4 Inhibition Attenuates Cardiac Dysfunction and Adverse Remodeling Following Myocardial Infarction in Rats with Experimental Diabetes. Cardiovascular Therapeutics, 2013, 31, 259-267.	1.1	56
38	Early-Outgrowth Bone Marrow Cells Attenuate Renal Injury and Dysfunction via an Antioxidant Effect in a Mouse Model of Type 2 Diabetes. Diabetes, 2012, 61, 2114-2125.	0.3	32
39	A Purpose-Synthesised Anti-Fibrotic Agent Attenuates Experimental Kidney Diseases in the Rat. PLoS ONE, 2012, 7, e47160.	1.1	37
40	The cardiac (pro)renin receptor is primarily expressed in myocyte transverse tubules and is increased in experimental diabetic cardiomyopathy. Journal of Hypertension, 2011, 29, 1175-1184.	0.3	37
41	Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 298, H1415-H1425.	1.5	106
42	Inhibition of Protein Kinase Câ€“Î² by Ruboxistaurin Preserves Cardiac Function and Reduces Extracellular Matrix Production in Diabetic Cardiomyopathy. Circulation: Heart Failure, 2009, 2, 129-137.	1.6	106
43	Effect of Ruboxistaurin on Urinary Transforming Growth Factor-Â in Patients With Diabetic Nephropathy and Type 2 Diabetes. Diabetes Care, 2007, 30, 995-996.	4.3	50
44	Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction. Journal of Molecular and Cellular Cardiology, 2005, 39, 213-221.	0.9	70